Brief: Targovax: Continued Survival Benefit In Oncos-102 Trial In Mesothelioma

Circio Holding ASA

23/02/2021 06:04

Feb 23 (Reuters) - Targovax ASA  TRVX.OL :
    * CONTINUED SURVIVAL BENEFIT IN TARGOVAX'S ONCOS-102 TRIAL IN MESOTHELIOMA
    * MEDIAN OVERALL SURVIVAL (MOS) HAS STILL NOT BEEN MET FOR RANDOMIZED FIRST-LINE PATIENTS
RECEIVING ONCOS-102 PLUS CHEMOTHERAPY
    * 21-MONTH ANALYSIS SHOWS THAT MOS WILL BE AT LEAST 20.5 MONTHS FOR RANDOMIZED FIRST-LINE
PATIENTS
RECEIVING ONCOS-102 PLUS CHEMOTHERAPY, COMPARED TO MOS OF 13.5 MONTHS IN CHEMOTHERAPY-ONLY
CONTROL GROUP

Source text for Eikon:  ID:nObibShbFa 
Further company coverage:  TRVX.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))